Vectus Biosystems Limited (AU:VBS) has released an update.
Vectus Biosystems Limited is advancing the commercialisation of its lead clinical drug, VB0004, while exploring licensing and partnership opportunities for its therapeutic portfolio, including collaborations with C14 Consulting Group in the USA. The company has completed Phase Ia/Ib human clinical trials for VB0004, which aim to treat fibrosis and hypertension, and reported no significant adverse events. Vectus is also focusing on cost reduction and securing future funding, with $977,000 received as a research and development refund supplementing its cash reserves.
For further insights into AU:VBS stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
